sprite-preloader
Anzeige
Mehr »
Samstag, 23.02.2019 Börsentäglich über 12.000 News von 595 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrNICE blames BioMarin for Brineura rejection after price talks break down
FrTakeda gout drug Uloric loses first-line approval after FDA confirms death risks
FrDoes Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?
FrCatalyst plays the R&D card to defend Firdapse's $375K sticker against Bernie Sanders' ire
FrBayer to cut 200 jobs at U.S. logistics center as it alters course for pharma
FrFiercePharmaAsia-GSK-Bharat vaccine deal; Dr. Reddy's rollercoaster; Sandoz sells U.S. generics
DoCongressman aims to break pharma's insulin 'pricing monopoly' by legalizing Canadian imports
DoNovo Nordisk nabs FDA nod for hemophilia A drug Esperoct but can't launch until 2020
DoJustice Department, SEC subpoenas put J&J's talc woes under federal microscope
DoBristol-Myers confirms activist Starboard has its shares. And it wants board seats, too
DoIt's not a Brexit problem, Sanofi says of epilepsy drug shortages
DoDespite 35 price hikes, Sanofi's net prices fell yet again in 2018
MiAllogene Therapeutics to build out facility for allogeneic CAR T treatments
MiPfizer switches RA patients to lower dose of fast-growing Xeljanz as safety issues arise in postmarketing study
Mi'Organic' growth and 'pivoting' at Bausch Health? One analyst begs to disagree
MiPfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
MiTeva, FTC enter expanded settlement barring certain 'pay-for-delay' deals for 10 years
MiEmergex preps for synthetic vaccines human testing with new R&D facility and key hire
MiMerck's Keytruda hits the skids in pivotal trial, putting its liver cancer nod at risk
MiNews of Note - Facebook, flu vaccines and more
DiPhilippine officials pull Dengvaxia's marketing license, but Sanofi asks them to reconsider
DiFormer AstraZeneca UK plant back up for sale, putting 270 jobs at risk
DiUnder-pressure Allergan backs a CEO-chairman job split-just not right now
DiActivist Starboard wants to know if Bristol investors support Celgene buy: report
DiPipeline-hungry Bayer antes up on Vitrakvi, just as Roche's would-be rival gets faster FDA review